Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.

NCT00563108 is registered in ClinicalTrials.gov with Hospital Authority, Hong Kong as lead sponsor.

NCT NCT00563108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00563108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.
Lead sponsor
Hospital Authority, Hong Kong
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2004
Completion date
December 31, 2008
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease, hematopoietic stem cell transplantation